Apixaban to prevent blood clots during treatment before bladder cancer surgery
Tests apixaban against no blood thinner in adults with muscle-invasive bladder cancer.
Key facts
- Who runs it
- HUS-Yhtymae
- Where
- Helsinki, Jyvaskyla, Kuopio, Oulu, Tampere, and Turku, FinlandSee the 6 sites
- Trial code
- Registry title
- Thromboprophylaxis with Apixaban during neoadjuvant therapy for muscle-invasive Bladder cancer
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 210 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2034
- Type of study
- Interventional
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with muscle-invasive bladder cancer who are planned to have chemotherapy or similar drug treatment before surgery to remove the bladder or chemoradiotherapy. Half will take apixaban to prevent blood clots; half will not.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Bladder cancer (muscle-invasive) with planned neoadjuvant systemic therapy before radical cystectomy or chemoradiotherapy
- Earlier treatment
- Must not currently take warfarin, LMWH, another DOAC or double anti-platelet medication
Main reasons for not taking part
- Active bleeding or high risk of serious bleeding, such as recent stomach or intestinal bleeding or bleeding in the skull within the past 6 months
- Pregnant or breast-feeding
- Known thrombophilia or known bleeding disorder
- Severe liver impairment or eGFR <30 mL/min/1.73 m2
- Known allergy to apixaban
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years
- Planned to receive neoadjuvant systemic therapy prior to radical cystectomy or chemoradiotherapy for bladder cancer
- Ability to provide written informed consent prior to study participation
Who cannot take part
- Previous randomization in this trial
- Known active bleeding or high risk of clinically significant bleeding (e.g., recent gastrointestinal bleeding or intracranial hemorrhage within the past 6 months)
- Taking strong inhibitors or inductors of both CYP 3A4 and P-glycoprotein, such as anti-seizure medications (e.g. phenytoin, fosphenytoin, carbamazepine), azole-antimycotics (e.g. ketoconazole, itraconazole), HIV-protease inhibitors (e.g. ritonavir, indinavir) and rifampicin
- Known bleeding disorder
- Known allergy to apixaban
- Current anticoagulation with warfarin, LMWH, another DOAC or double anti-platelet medication
- Substantial liver impairment (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2 x ULN or total bilirubin ≥ 1.5 x ULN)
- eGFR <30 mL/min/1.73 m2
- Platelet count <100 × 109/L (that is, 100 000 mg/L)
- Hb <90 g/L (that is, <9 g/dL)
- Pregnant or breast-feeding female patients
- Women who have had periods in the last 12 months and who are not using highly reliable contraception: (i) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); ii) progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); iii) intrauterine device (IUD); iv) intrauterine hormone-releasing system (IUS); v) bilateral tubal occlusion; vi) vasectomized partner; and vii) sexual abstinence from heterosexual intercourse during the entire period of risk associated with the study treatments
- Any reason why, in the opinion of the investigator(s), the patient should not participate
- Known thrombophilia
Where in Finland
- HUS-YhtymaeHelsinki, FinlandNot yet recruiting
- Wellbeing Services County Of Central FinlandJyvaskyla, FinlandNot yet recruiting
- Kuopio University HospitalKuopio, FinlandNot yet recruiting
- Oulu University HospitalOulu, FinlandNot yet recruiting
- Tampere University HospitalTampere, FinlandNot yet recruiting
- Turku University HospitalTurku, FinlandNot yet recruiting
About the trial
What the trial wants to find out
To evaluate, in adult patients with planned NAT for MIBC followed by radical treatment, the benefits and harms of thromboprophylaxis with apixaban (oral factor Xa inhibitor) DOAC therapy in addition to standard of care compared with standard of care without anticoagulant therapy. NAT will be administered according to local standard of care and may include, but is not limited to, gemcitabine-cisplatin, dose-dense MVAC, perioperative durvalumab with neoadjuvant gemcitabine-cisplatin, or enfortumab vedotin plus pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer
- Plain-language title
- Apixaban to prevent blood clots during treatment before bladder cancer surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 July 2026